Efficacy and Safety of Autologous Stromal Vascular Fraction in the Treatment of Empty Nose Syndrome.
- Author:
Do Youn KIM
1
;
Hye Ran HONG
;
Eun Wook CHOI
;
Sang Won YOON
;
Yong Ju JANG
Author Information
- Publication Type:Original Article
- Keywords: Empty Nose Syndrome; Stem Cells; Stromal Vascular Fraction; Sino-Nasal Outcome Test-25; Cytokines
- MeSH: Abdominal Fat; Absorption; Biomarkers; Calcitonin Gene-Related Peptide; Clinical Study; Cytokines; Enzyme-Linked Immunosorbent Assay; Humans; Interleukin-8; Interleukins; Methods; Nasal Cavity; Nasal Mucosa; Nervous System; Nose*; Patient Satisfaction; Polyurethanes; Postoperative Complications; Prospective Studies; Stem Cells; Turbinates
- From:Clinical and Experimental Otorhinolaryngology 2018;11(4):281-287
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVES: Regenerative treatment using stem cells may serve as treatment option for empty nose syndrome (ENS), which is caused by the lack of turbinate tissue and deranged nervous system in the nasal cavity. We aimed to assess the efficacy and safety of the autologous stromal vascular fraction (SVF) in the treatment of ENS. METHODS: In this prospective observational clinical study, we enrolled 10 ENS patients who volunteered to undergo treatment of ENS through the injection of autologous SVF. Data, including demographic data, pre- and postoperative Sino-Nasal Outcome Test-25 (SNOT-25) scores, overall patient satisfaction, and postoperative complications, were prospectively collected. Nasal secretion was assessed using the polyurethane foam absorption method, and the levels of biological markers were analyzed in both ENS group and control group using enzyme-linked immunosorbent assay. The SVF extracted from abdominal fat was diluted and injected into both inferior turbinates. RESULTS: Among the 10 initial patients, one was excluded from the study. Subjective satisfaction was rated as “much improved” in two and “no change” in seven. Among the improved patients, the mean preinjection SNOT-25 score was 55.0 and the score at 6 months after injection was 19.5. However, the average SNOT-25 score of nine participants at 6 months after injection (mean±standard deviation, 62.4±35.8) did not differ significantly from the baseline SNOT-25 score (70.1±24.7, P>0.05, respectively). Among the various inflammatory markers assessed, the levels of interleukin (IL)-1β, IL-8, and calcitonin gene-related peptide were significantly higher in ENS patients. Compared with preinjection secretion level, the nasal secretions from SVF-treated patients showed decreased expressions of IL-1β and IL-8 after injection. CONCLUSION: Although SVF treatment appears to decrease the inflammatory cytokine levels in the nasal mucosa, a single SVF injection was not effective in terms of symptom improvement and patient satisfaction. Further trials are needed to identify a more practical and useful regenerative treatment modality for patients with ENS.
